MCM
MRSN

Moore Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Moore Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,120
Closed -$174K – 558
2023
Q2 		$174K Buy
+2,120
New +$310K ﹤0.01% 381

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Moore Capital Management's MRSN Position: Q2 2019 in Review

Moore Capital Management sold out of Mersana Therapeutics (MRSN) in Q2 2019, closing a stake of 800 shares — an estimated $105K sold.

Moore Capital Management first reported a position in MRSN in Q1 2019 and held it in 1 quarter. The position peaked at $105K in Q1 2019. 77 funds tracked by Wall St. Rank hold MRSN as of Q2 2019.

  • Moore Capital Management reported no remaining Mersana Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Moore Capital Management sold 800 Mersana Therapeutics shares in Q2 2019, an estimated $105K.
  • Moore Capital Management first reported a position in Mersana Therapeutics in Q1 2019 and held it in 1 quarter.
  • Moore Capital Management's Mersana Therapeutics position peaked at $105K in Q1 2019.
  • 77 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2019.

Based on Moore Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.